Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Condition: Hemophilia A With Inhibitor Intervention: Drug: SCT800 and Daratumumab Sponsors: Institute of Hematology & Blood Diseases Hospital; Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Condition: Hemophilia A With Inhibitor Intervention: Drug: SCT800 and Daratumumab Sponsors: Institute of Hematology & Blood Diseases Hospital; Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Condition: Hemophilia A With Inhibitor Intervention: Drug: SCT800 and Daratumumab Sponsors: Institute of Hematology & Blood Diseases Hospital; Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Condition: Hemophilia A With Inhibitor Intervention: Drug: SCT800 and Daratumumab Sponsors: Institute of Hematology & Blood Diseases Hospital; Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Condition: Hemophilia A With Inhibitor Intervention: Drug: SCT800 and Daratumumab Sponsors: Institute of Hematology & Blood Diseases Hospital; Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Reliability and Validity of the Turkish Version of the PedHAL
Conditions: Hemophilia; Hemophilia A, Severe; Hemophilia B Intervention: Sponsor: Hasan Kalyoncu University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Research and Pipeline Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens
Marstacimab, if approved, has the potential to become the first once-weekly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 30, 2023 Category: Pharmaceuticals Source Type: clinical trials
Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia
Conditions: Hemophilia A; Hemophilia B Interventions: Other: Closed Chain Exercise Group; Other: Proprioceptive Exercise Group Sponsor: Bahçeşehir University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
Conditions: Haemophilia A; Haemophilia A With Inhibitors Intervention: Drug: NNC0365-3769 (Mim8) PPX Sponsor: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials
